$4.99
8.78% yesterday
Nasdaq, Aug 12, 10:00 pm CET
ISIN
US30049G1040
Symbol
EVOK

Evoke Pharma, Inc. Stock price

$4.99
-0.75 12.99% 1M
+0.00 0.00% 6M
+0.57 12.90% YTD
-0.70 12.30% 1Y
-28.25 84.99% 3Y
-738.05 99.33% 5Y
-650.21 99.24% 10Y
-1,685.57 99.70% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
-0.48 8.78%
ISIN
US30049G1040
Symbol
EVOK
Industry

Key metrics

Basic
Market capitalization
$8.2m
Enterprise Value
$550.0k
Net debt
positive
Cash
$12.6m
Shares outstanding
1.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
0.7 | 0.5
EV/Sales
0.1 | 0.0
EV/FCF
negative
P/B
1.4
Financial Health
Equity Ratio
40.2%
Return on Equity
-76.1%
ROCE
-84.4%
ROIC
-
Debt/Equity
0.9
Financials (TTM | estimate)
Revenue
$11.6m | $16.2m
EBITDA
- | -
EBIT
$-5.0m | $-2.5m
Net Income
$-5.1m | $-1.5m
Free Cash Flow
$-3.9m
Growth (TTM | estimate)
Revenue
90.0% | 57.8%
EBITDA
- | -
EBIT
26.1% | 51.6%
Net Income
28.8% | 71.4%
Free Cash Flow
34.6%
Margin (TTM | estimate)
Gross
97.4%
EBITDA
- | -
EBIT
-43.2%
Net
-43.8% | -9.5%
Free Cash Flow
-33.4%
More
EPS
$-2.0
FCF per Share
$-2.6
Short interest
18.2%
Employees
3
Rev per Employee
$3.4m
Show more

Is Evoke Pharma, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Evoke Pharma, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Evoke Pharma, Inc. forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Evoke Pharma, Inc. forecast:

Buy
86%
Hold
14%

Financial data from Evoke Pharma, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
12 12
90% 90%
100%
- Direct Costs 0.31 0.31
29% 29%
3%
11 11
93% 93%
97%
- Selling and Administrative Expenses 16 16
30% 30%
140%
- Research and Development Expense 0.05 0.05
58% 58%
0%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -5 -5
26% 26%
-43%
Net Profit -5.08 -5.08
29% 29%
-44%

In millions USD.

Don't miss a Thing! We will send you all news about Evoke Pharma, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Evoke Pharma, Inc. Stock News

Neutral
GlobeNewsWire
7 days ago
Extends market exclusivity for GIMOTI® to November 2038, nearly two additional years beyond original 2036 projection Extends market exclusivity for GIMOTI® to November 2038, nearly two additional years beyond original 2036 projection
Neutral
GlobeNewsWire
about one month ago
SOLANA BEACH, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a U.S. patent applicatio...
Neutral
GlobeNewsWire
3 months ago
Q1 2025 Net Product Sales Increased 77% Year-over-Year to $3.1 Million Sustained Momentum Driven by Growing Prescriber Adoption and Repeat Patient Use SOLANA BEACH, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders with an emphasis on GIMOTI®, today announced financial results ...
More Evoke Pharma, Inc. News

Company Profile

Evoke Pharma, Inc. is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. It develops Gimoti, with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. The company was founded by Matthew J. D'Onofrio, Cam L. Garner, Scott L. Glenn, and David A. Gonyer in January 2007 and is headquartered in Solana Beach, CA.

Head office United States
CEO Matthew D'Onofrio
Employees 3
Founded 2007
Website evokepharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today